ProGen

Since its establishment in 1998, ProGen, a research and development-oriented biopharmaceutical drug development enterprise, has maintained continuous cooperation and partnerships with the best pharmaceutical companies in South Korea. ProGen's platform technology is multi-target fusion protein technology, aimed at creating value and sustaining growth by discovering various new drug candidates through co-development or external technology transfer. ProGen is utilizing its expertise in immunology-based new drug development to develop treatments for metabolic diseases, immune diseases, and immuno-oncology drugs, while focusing on innovative new drug development through open innovation both in China and internationally.